BRAF and non-small cell lung carcinoma: On the one hand, this result is consistent with previous real-world study data showing that ICI efficacies against BRAF-, HER2-, MET-, or RET-NSCLC patients were close to the efficacy observed in unselected NSCLC patients (29).